Resolution of cisplatin-induced fatigue does not require endogenous interleukin-10 in male mice. Academic Article uri icon


  • Based on previous results showing a pivotal role of endogenous interleukin-10 (IL-10) in the recovery from cisplatin-induced peripheral neuropathy, the present experiments were carried out to determine whether this cytokine plays any role in the recovery from cisplatin-induced fatigue in male mice. Fatigue was measured by decreased voluntary wheel running in mice trained to run in a wheel in response to cisplatin. Mice were treated with a monoclonal neutralizing antibody (IL-10na) administered intranasally during the recovery period to neutralize endogenous IL-10. In the first experiment, mice were treated with cisplatin (2.83mg/kg/day) for five days and IL-10na (12g/day for three days) five days later. In the second experiment, they were treated with cisplatin (2.3mg/kg/day for 5 days twice at a five-day interval) and IL10na (12g/day for three days) immediately after the last injection of cisplatin. In both experiments, cisplatin decreased body weight and reduced voluntary wheel running. However, IL-10na did not impair recovery from these effects. These results show that the recovery from the cisplatin-induced decrease in wheel running does not require endogenous IL-10 in contrast to the recovery from cisplatin-induced peripheral neuropathy.

published proceedings

  • Behav Brain Res

author list (cited authors)

  • Scott, K., Boukelmoune, N., Taniguchi, C., West, A. P., Heijnen, C. J., & Dantzer, R.

citation count

  • 0

complete list of authors

  • Scott, Kiersten||Boukelmoune, Nabila||Taniguchi, Cullen||West, A Phillip||Heijnen, Cobi J||Dantzer, Robert

publication date

  • April 2023